Loading…
Acrivon Therapeutics Inc Is A Clinical-Stage Biopharmaceutical Company Developing Oncology Medicines That The Firm Matches To Patients Whose Tumors Are Predicted To Be Sensitive To Each Specific Medicine By Utilizing Its Proteomics-Based Patient Responder Identification Platform. The Company'S Pipeline Includes Acr-368, Referred To As Prexasertib, A Targeted Oncology Asset, As Well As Preclinical Stage Pipeline Programs Targeting Critical Nodes In The Dna Damage Response And Cell Cycle Regulation Pathways, Including Wee1, A Protein Kinase, And Pkmyt1; Acr-2316 A Selective, Dual Wee1/Pkmyt1 Inhibitor; And Acr-6840, A Development Candidate Targeting Cdk11. It Has One Reportable Segment Focused On The Research And Development Of Precision Oncology Therapies.